WALLSTENT ILIAC RP Endoprosthesis
Boston Scientific Scimed, Inc. · Decision date May 6, 2026
What did the FDA decide?
FDA records P940019/S067 as a supplement to PMA P940019, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 6, 2026.
FDA approval order statement
the extension of maximum transfer time between preconditioning cell to sterilization chamber during routine production for Ethylene Oxide(EtO) sterilization
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- May 6, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P940019/S067
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Scimed, Inc.
- Product code
- NIO
- Decision code
- OK30
- Decision date
- May 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, ILIAC.
- Applicant
- Boston Scientific Scimed, Inc.
- Product code
- NIO
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P940019/S067 received
Application receipt date recorded by FDA.
P940019/S067 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P940019. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code NIO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cook Ireland, Ltd. | PMA supplement | Nov 6, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
S.M.A.R.T. CONTROL Nitinol Stent SystemP020036/S061 | Cordis US Corporation | PMA supplement | Oct 15, 2026 | FDA |
| Biotronik AG | PMA supplement | Sep 11, 2026 | FDA | |
Epic Vascular Self-Expanding Stent SystemP110035/S079 | Boston Scientific Corp | PMA supplement | Aug 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Scimed, Inc.
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- One Scimed Pl., Maple Grove, MN, 55311
Sources and methodology
- Original FDA record: P940019/S067
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



